BWBarbara Waddell

Barbara Waddell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Barbara Waddell has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A population-based cohort study to establish clinical characteristics and outcomes of patients experiencing methicillin-sensitive Staphylococcus aureus bacteremia as a function of the cefazolin high inoculum effect

    by Alexander J. Kipp, Kristine Du, Barbara Wadell, Stephen Robinson, Julianna Svishchuk, John M. Conly, Annegret Ulke-Lemee, Maryam Mapar, Ian Lewis, Daniel B. Gregson, et al.

    Background: Staphylococcus aureus bacteremia is a leading cause of morbidity and mortality. Several phenotypes (e.g. methicillin-resistance) influence patient outcomes. The high inoculum effect (HIE) is characterized by reduced susceptibility to beta-lactam antibiotics, most notably cefazolin, at high inoculums in-vitro . Methods: A population-based cohort was used to assess all MSSA bacteremia in Calgary, Alberta, from 2012-14 and 2019 (n=1.5 million). Isolates underwent genomic sequencing and cefazolin susceptibility testing at 10 5 and 10 7 CFU/ml where the HIE was defined as a 4X-increase in minimum-inhibitory concentration (MIC) and pronounced (PIE) defined as MIC≥16 ug/ml at 10 7 CFU/ml. Results: The incidence of MSSA bacteremia with HIE decreased from 38.9 to 24.2% between the two time periods. Patients infected with HIE phenotype could not be differentiated based on demographics, source of bacteremia, or clinical biomarkers at presentation. Sequencing confirmed associations of HIE with blaZ A, agr3, and clonal complex 30. HIE was not associated with outcomes including clearance-time and all-cause mortality when assessed in aggregate or as a function of treatment. Relapses, however, were only documented with cefazolin. PIE was observed in 3.7% of isolates and was associated with significant increased all-cause 180-day mortality, irrespective of treatment, but not at one year. Discussion: The HIE, but not PIE, is common in an unselected general population cohort. Neither demographics nor clinical biomarkers can be used to predict HIE. If there is a deleterious impact of this phenotype on patient outcomes, it is modest and may be masked by empiric therapy provided prior to MSSA bacteremia confirmation. Importance Statement: A prospective cohort study by Miller et al. (2018) observed a significant increase in 30-day mortality in individuals experiencing methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia, with isolates exhibiting the high-inoculum effect (HIE) phenotype, when treated with the cefazolin. Our study sought to understand the epidemiology and impact of the HIE, using a population-based study design thereby mitigating the selection bias associated with other conventional cohort studies (focused on specific hospitals, at-risk groups, or clinics). We address the effects of HIE on clinical outcomes, predictive factors, and associated genomic contributors for the HIE phenotype within an unbiased population. These data are important for clinicians by highlighting if it is possible to predict HIE phenotype based on clinical and genomic factors, and to establish if cefazolin use associates with worse outcomes when MSSA causing bacteremia exhibits the HIE phenotype.

  • Open Access

    Group B streptococcus (GBS) is an important pathogen in human disease- but what about in cystic fibrosis?

    by Kate Skolnik, Austin Nguyen, Christina S. Thornton, Barbara Waddell, Tyler Williamson, Harvey R. Rabin, Michael D. Parkins

    Group B Streptococcus (GBS) is a common commensal capable of causing severe invasive infections. Most GBS infections occur in neonates (often as pneumonia). GBS can also cause infection in adults with diabetes and other immunological impairments but rarely leads to pneumonia in adults. GBS has occasionally been found in the sputum of Cystic Fibrosis (CF) patients, an inherited condition known for progressive lung disease. However, the epidemiology and clinical significance of GBS in CF are not understood. We retrospectively reviewed a large single-centre adult CF population with an associated comprehensive, prospectively collected bacterial biobank beginning in 1978. We identified all individuals with GBS isolated from their sputum on at least one occasion. The primary outcome was risk of pulmonary exacerbation (PEx) at the time of the first GBS isolate compared to the preceding visit. Secondary outcomes included determining: prevalence of GBS infection in a CF population, whether GBS infections where transient or persistent, whether GBS strains were shared among patients, change in % predicted FEV1 at the time of GBS isolate compared to the preceding visit, PEx frequency after the first GBS isolate, change in % predicted FEV1 after the first GBS isolate, and complications of GBS infection. GBS was uncommon, infecting 3.5% (11/318) adults within our cohort. Only three individuals developed persistent GBS infection, all lasting > 12 months. There were no shared GBS strains among patients. PEx risk was not increased at initial GBS isolation (RR 5.0, CI 0.69–36.1, p=0.10). In the two years preceding initial GBS isolation compared to the two following years, there was no difference in PEx frequency (median 2, range 0–4 vs 1, range 0 to 5, respectively, p=0.42) or lung function decline, as measured by % predicted FEV1, (median −1.0%, range −19 to 7% vs median −6.0%, range −18 to 22%, p=0.86). There were no invasive GBS infections. In adults with CF, GBS is uncommon and is generally a transient colonizer of the lower airways. Despite the presence of structural lung disease and impaired innate immunity in CF, incident GBS infection did not increase PEx risk, PEx frequency, rate of lung function decline, or other adverse clinical outcomes.


  • Reemergence of Lower-Airway Microbiota in Lung Transplant Patients with Cystic Fibrosis

    by Saad A. Syed, Fiona J. Whelan, Barbara Waddell, Harvey R. Rabin, Michael D. Parkins, Michael G. Surette

    Rationale: Chronic lung infections are a hallmark of cystic fibrosis; they are responsible for progressive airway destruction and ultimately lead to respiratory death or the requirement for life-saving bilateral lung transplant. Furthermore, recurrent isolation of airway pathogens such as Pseudomonas aeruginosa in the allograft after transplant is associated with adverse outcomes, including bronchiolitis obliterans syndrome and acute infections. Little information exists on the impact of bilateral lung transplant on the lower-airway microbiota. Objectives: To compare, at a microbiome and single-pathogen level (P. aeruginosa), the bacterial communities in pre- and post-transplant samples. Methods: We retrospectively accessed our biobank of sputum samples and sputum-derived bacterial pathogens for patients who had matched samples, including those who were clinically stable before transplant, those who had a pulmonary exacerbation before transplant, and those who had pulmonary exacerbation after transplant. We used 16S ribosomal RNA gene sequencing to characterize the lower-airway microbiome of 14 adult transplant patients with cystic fibrosis. Genotyping and phenotyping of P. aeruginosa isolates from 12 of these patients with matched isolates was performed. Measurements and Main Results: Although α-diversity (richness and evenness) of patient microbiomes was similar before and after transplant, β- diversity (core microbiome composition) measures stratified patients evenly into two groups with more similar and more dissimilar communities. P. aeruginosa strains isolated before transplant were found to reemerge in 11 of 12 patients; however, phenotypic variation was observed. Conclusions: These findings indicate that recolonization by P. aeruginosa after transplant is almost always strain specific, suggesting a within-host source. The polymicrobial colonization of the airways after transplant does not always reflect the pretransplant sputum microbiota.


  • Open Access

    Clinical implications and characterization of Group A Streptoccoccus infections in adults with cystic fibrosis

    by Kate Skolnik, Austin Nguyen, Ranjani Somayaji, Christina S. Thornton, Barbara Waddell, Michael G. Surette, Harvey R. Rabin, Michael D. Parkins


  • Open Access

    Infection control knowledge, beliefs and behaviours amongst cystic fibrosis patients with epidemic Pseudomonas aeruginosa

    by R. Somayaji, B. Waddell, M. L. Workentine, M. G. Surette, N. P. Brager, H. R. Rabin, M. D. Parkins

    Epidemic P. aeruginosa (ePA) infections are common in cystic fibrosis (CF) and have been associated with accelerated clinical decline. Factors associated with ePA are unclear, and evidence based infection control interventions are lacking. We prospectively collect all bacterial pathogens from adult CF patients. We performed PA strain typing on retrospectively collected enrolment samples and recent isolates to identify patients infected with ePA. All patients attending our clinic were approached to complete a survey on infection control knowledge, beliefs and exposures. We analyzed responses of those with ePA relative to the entire cohort without ePA as well as those infected with unique strains of P. aeruginosa to assess for risk factors for ePA and differences in infection control knowledge, beliefs or behaviours. Of 144 participants, 30 patients had ePA (two Liverpool epidemic strain, 28 Prairie epidemic strain), 83 % of which had established infection prior to transition to the adult clinic. Risk of concomitant infecting pathogens was no different between groups although, Staphylococcus aureus and non-tuberculous mycobacteria were less common in those with ePA. Patients with ePA were more likely to have attended CF-camp and have a history of CF fundraising. Patients with ePA did not differ with respect to beliefs regarding pathogens or transmission risk, except they believed indirect contact posed little risk. Furthermore, patients with ePA were more likely to continue to associate with others with CF despite extensive counselling. Use of peer-peer online networking was minimal in both groups. Infections with ePA are closely linked to past exposures, now routinely discouraged. As socialization is the greatest risk factor for ePA, infection control strategies for ePA must focus on discouraging face-to-face interactions amongst CF patients. As peer support remains a desire amongst patients, investment in technologies and strategies that enable indirect communication and support are required.